US2020354422A1PendingUtilityA1

Methods for cardiomyocyte survival, proliferation or differentiation by nrg-2

71
Assignee: ACORDA THERAPEUTICS INCPriority: May 23, 2000Filed: Jun 5, 2020Published: Nov 12, 2020
Est. expiryMay 23, 2020(expired)· nominal 20-yr term from priority
Inventors:Mark Marchionni
A61P 25/00A61K 38/1883A61K 45/00G01N 2800/325C07K 14/4756A61P 21/00A61P 25/28A61P 9/04A61P 35/04A61P 9/06A61K 38/1709A61P 35/00A61K 38/17A61K 38/00A61K 2039/55516A61K 2039/6031C12N 2830/85A61K 35/34G01N 2333/4756C07K 14/47A61K 47/42A61P 25/16A01K 2217/05A61P 27/00G01N 2333/71A61K 38/16G01N 2800/32C07K 14/475G01N 2800/52C07K 14/71C07K 14/00A61K 38/18A61P 9/10C07K 2319/00G01N 2333/485A61P 21/04A61P 9/00A61P 43/00A61K 2300/00G01N 33/5061C07K 14/485A61P 21/02A61P 25/02G01N 33/68G01N 2500/10A61P 9/12
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 69 . (canceled) 
     
     
         70 . A composition comprising a recombinant NRG-2 polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 4 for the treatment or prophylaxis of a pathophysiological condition of the nervous system in a subject, and
 wherein said NRG-2 polypeptide is sufficient to induce myelination of a neuronal cell by a glial cell.   
     
     
         71 . The composition according to  claim 70 , wherein said pathophysiological condition is selected from the group consisting of multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's Disease, and spinal cord injury. 
     
     
         72 . The composition according to  claim 70 , wherein said pathophysiological condition is multiple sclerosis. 
     
     
         73 . The composition according to  claim 70 , wherein said pathophysiological condition is amyotrophic lateral sclerosis. 
     
     
         74 . The composition according to  claim 70 , wherein said pathophysiological condition is Parkinson's Disease. 
     
     
         75 . The composition according to  claim 70 , wherein said pathophysiological condition is spinal cord injury. 
     
     
         76 . The composition according to  claim 70 , wherein said glial cell is a Schwann cell or an oligodendrocyte. 
     
     
         77 . The composition according to  claim 70 , wherein said subject is a human. 
     
     
         78 . A kit for the analysis of a NRG-2 polypeptide of a test subject, said kit comprising the antibody that specifically binds to a NRG-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NOs: 2 or 4.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.